Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 16/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245050 | 0.87 | IDH1 (0.58) | IDH1HSD11B1TYRO3 | |
| SCHEMBL2365627 | 0.78 | IDH1 (0.57) | IDH1HSD11B1TYRO3 | |
| SCHEMBL16530082 | 0.75 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL1675970 | 0.75 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL15100598 | 0.75 | HSD11B1 (0.52) | IDH1HSD11B1 | |
| SCHEMBL15090617 | 0.75 | HSD11B1 (0.52) | IDH1HSD11B1 | |
| SCHEMBL16940730 | 0.75 | HSD11B1 (0.77) | HSD11B1 | |
| SCHEMBL16666616 | 0.75 | HSD11B1 (0.77) | HSD11B1 | |
| SCHEMBL2365647 | 0.72 | RHOA (0.74) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14261033 | 0.71 | HSD11B1 (0.56) | IDH1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | claimed |
| CN-102223797-A | Adamantyl benzamide compounds | HIGH POINT PHARMACEUTICALS LLC | 2011-10-19 | — | — | CN | claimed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | claimed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | claimed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| CN-102223797-A | Adamantyl benzamide compounds | HIGH POINT PHARMACEUTICALS LLC | 2011-10-19 | — | — | CN | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | IDH1 122/4885HSD11B1 1/4885KDM4E 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.